



European Medicines Agency  
Evaluation of Medicines for Human Use

London, 19 February 2009  
Doc.Ref. EMEA/CHMP/121120/2009

**COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE**  
**POST-AUTHORISATION SUMMARY OF POSITIVE OPINION\***  
**for**  
**AVASTIN**

International Nonproprietary Name (INN): *bevacizumab*

On 19 February 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion\*\* to recommend the variation to the terms of the marketing authorisation for the medicinal product Avastin. The Marketing Authorisation Holder for this medicinal product is Roche Registration Ltd..

The CHMP adopted the removal of a contraindication as follows:  
“Avastin is contraindicated in patients with untreated CNS metastases”.

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

---

\* Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the Opinion.

\*\* Marketing Authorisation Holders may request a re-examination of any CHMP opinion, provided they notify the EMEA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.